OCS
Price
$16.98
Change
-$0.03 (-0.18%)
Updated
Dec 20, 04:59 PM (EDT)
SNSE
Price
$0.45
Change
+$0.02 (+4.65%)
Updated
Dec 20, 04:59 PM (EDT)
73 days until earnings call
Ad is loading...

OCS vs SNSE

Header iconOCS vs SNSE Comparison
Open Charts OCS vs SNSEBanner chart's image
Oculis Holding AG
Price$16.98
Change-$0.03 (-0.18%)
Volume$1.49K
CapitalizationN/A
Sensei Biotherapeutics
Price$0.45
Change+$0.02 (+4.65%)
Volume$5.1K
CapitalizationN/A
OCS vs SNSE Comparison Chart
Loading...
OCS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNSE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCS vs. SNSE commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCS is a Hold and SNSE is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (OCS: $16.98 vs. SNSE: $0.45)
Brand notoriety: OCS and SNSE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCS: 27% vs. SNSE: 46%
Market capitalization -- OCS: $712.23M vs. SNSE: $11.32M
OCS [@Biotechnology] is valued at $712.23M. SNSE’s [@Biotechnology] market capitalization is $11.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCS’s FA Score shows that 0 FA rating(s) are green whileSNSE’s FA Score has 1 green FA rating(s).

  • OCS’s FA Score: 0 green, 5 red.
  • SNSE’s FA Score: 1 green, 4 red.
According to our system of comparison, both OCS and SNSE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCS’s TA Score shows that 5 TA indicator(s) are bullish while SNSE’s TA Score has 2 bullish TA indicator(s).

  • OCS’s TA Score: 5 bullish, 4 bearish.
  • SNSE’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, OCS is a better buy in the short-term than SNSE.

Price Growth

OCS (@Biotechnology) experienced а -0.64% price change this week, while SNSE (@Biotechnology) price change was +2.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

OCS is expected to report earnings on Feb 28, 2023.

SNSE is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCS($712M) has a higher market cap than SNSE($11.3M). OCS YTD gains are higher at: 51.202 vs. SNSE (-34.986). SNSE has higher annual earnings (EBITDA): -28.38M vs. OCS (-68.79M). OCS has more cash in the bank: 105M vs. SNSE (47M). OCS has less debt than SNSE: OCS (1.24M) vs SNSE (4.47M). OCS (0) and SNSE (0) have equivalent revenues.
OCSSNSEOCS / SNSE
Capitalization712M11.3M6,301%
EBITDA-68.79M-28.38M242%
Gain YTD51.202-34.986-146%
P/E Ratio63.08N/A-
Revenue00-
Total Cash105M47M223%
Total Debt1.24M4.47M28%
TECHNICAL ANALYSIS
Technical Analysis
OCSSNSE
RSI
ODDS (%)
Bearish Trend 3 days ago
46%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
29%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
55%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
44%
Bullish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
55%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
70%
Bullish Trend 28 days ago
73%
Declines
ODDS (%)
Bearish Trend 3 days ago
61%
Bearish Trend 11 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
33%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
55%
N/A
View a ticker or compare two or three
Ad is loading...
OCS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNSE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DHFYX12.910.18
+1.41%
Diamond Hill Large Cap Concentrated Y
BIAWX54.650.76
+1.41%
Brown Advisory Sustainable Growth Inv
IIVAX29.280.33
+1.14%
Transamerica Small/Mid Cap Value A
TNBIX18.720.12
+0.62%
1290 SmartBeta Equity I
RIVDX16.09-0.06
-0.37%
American Funds International Vntg R-2

OCS and

Correlation & Price change

A.I.dvisor tells us that OCS and GRI have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OCS and GRI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCS
1D Price
Change %
OCS100%
-0.18%
GRI - OCS
32%
Poorly correlated
-3.90%
PRAX - OCS
29%
Poorly correlated
+5.05%
SNSE - OCS
27%
Poorly correlated
+4.63%
CUE - OCS
27%
Poorly correlated
-0.98%
ENSC - OCS
26%
Poorly correlated
+1.89%
More

SNSE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNSE has been loosely correlated with VSTM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SNSE jumps, then VSTM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNSE
1D Price
Change %
SNSE100%
+4.63%
VSTM - SNSE
49%
Loosely correlated
-5.63%
ALZN - SNSE
40%
Loosely correlated
-11.20%
FATE - SNSE
36%
Loosely correlated
+1.20%
GRI - SNSE
34%
Loosely correlated
-3.90%
GOSS - SNSE
34%
Loosely correlated
-0.11%
More